Who is sponsoring NCT03828279?

NCT03828279 is sponsored by HAE Global Registry Foundation.

What drugs are being tested in NCT03828279?

Interventions in NCT03828279: functional and antigenic C1 inhibitor.

What condition does NCT03828279 study?

NCT03828279 studies Hereditary Angioedema Type I and II.

Is NCT03828279 still recruiting?

NCT03828279 is currently status unknown. Last updated 5 February 2019.

Last reviewed 2019-02-05 · How we verify

NCT03828279: HGR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II

Status unknown Last updated 5 February 2019

What this trial tests

trial testing functional and antigenic C1 inhibitor in Hereditary Angioedema Type I and II in 220 participants. Status unknown.

Timeline

1 October 2017

Primary endpoint
31 December 2019

31 December 2023

Quick facts

Lead sponsor	HAE Global Registry Foundation
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	220
Start date	1 October 2017
Primary completion	31 December 2019
Estimated completion	31 December 2023
Sites	1 location across Italy

Drugs / interventions tested

functional and antigenic C1 inhibitor

Conditions studied

Hereditary Angioedema Type I and II — all drugs for Hereditary Angioedema Type I and II →

Sponsor

HAE Global Registry Foundation

Who can join

Eligibility, any sex, with Hereditary Angioedema Type I and II. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this international hereditary angioedema (HAE) register is to collect homogeneous clinical and laboratory data on patients with HAE type I and II gathering better information on the natural course of the disease and detecting therapeutic options to manage it.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Lanadelumab Injection Treatment For The Prevention Of Hereditary Angioedema (HAE): Design, Development And Place In Therapy.
Bova M, Valerieva A, Wu MA, Senter R, et al · · 2019 · cited 8× · PMID 31695331 · DOI 10.2147/dddt.s192475
Delays and Barriers Related to the Treatment of Hereditary Angioedema Attacks in Italy.
Cancian M, Accardo P, Arcoleo F, Giardino F, et al · · 2025 · cited 1× · PMID 40671362 · DOI 10.1111/all.16643
The Neglected Older Adults in Hereditary Angioedema: Insights From the ITACA Registry.
Perego F, Marcelli AC, Senter R, Zingale LC, et al · · 2026 · PMID 42166534 · DOI 10.1002/clt2.70171
Ecological momentary assessments for patients with hereditary angioedema: a feasibility and acceptability controlled study.
Parati M, Ranucci L, Cesoni Marcelli A, Zingale LC, et al · · 2025 · PMID 41602209 · DOI 10.3389/fdgth.2025.1693550
Abstracts of 11th C1-inhibitor Deficiency & Angioedema Workshop
· 2019

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03828279 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by HAE Global Registry Foundation
Last refreshed: 5 February 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03828279.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing